Abstract:Rejection of solid organ transplant and graft versus host disease (GvHD) continue to be challenging in post transplantation management. The introduction of calcineurin inhibitors dramatically improved recipients' short-term prognosis. However, long-term clinical outlook remains poor, moreover, the lifelong dependency on these toxic drugs leads to chronic deterioration of graft function, in particular the renal function, infections and de-novo malignancies. These observations led investigators to identify alternative therapeutic options to promote long-term graft survival, which could be used concomitantly, but preferably, replace pharmacologic immunosuppression as standard of care. Adoptive T cell (ATC) therapy has evolved as one of the most promising approaches in regenerative medicine in the recent years. A range of cell types with disparate immunoregulatory and regenerative properties are actively being investigated as potential therapeutic agents for specific transplant rejection, autoimmunity or injury-related indications. A significant body of data from preclinical models pointed to efficacy of cellular therapies. Significantly, early clinical trial observations have confirmed safety and tolerability, and yielded promising data in support of efficacy of the cellular therapeutics. The first class of these therapeutic agents commonly referred to as advanced therapy medicinal products have been approved and are now available for clinical use. Specifically, clinical trials have supported the utility of CD4 + CD25+FOXP3+ regulatory T cells (Tregs) to minimize unwanted or overshooting immune responses and reduce the level of pharmacological immunosuppression in transplant recipients. Tregs are recognized as the principal orchestrators of maintaining peripheral tolerance, thereby blocking excessive immune responses and prevent autoimmunity. Here, we summarize rationale for the adoptive Treg therapy, challenges in manufacturing and clinical experiences with this novel living drug and outline future perspectives of its use in transplantation.

Prospects of the Use of Cell Therapy to Induce Immune Tolerance

Regulatory T Cell Therapy for the Induction of Clinical Organ Transplantation Tolerance

Targeting Lymphoid Tissues to Promote Immune Tolerance

Cellular strategies to induce immune tolerance after liver transplantation: Clinical perspectives

Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions

T Regulatory Cells As an Immunotherapy for Transplantation

Genetically modified immunomodulatory cell-based biomaterials in tissue regeneration and engineering

Twisting Immune Responses for Allogeneic Stem Cell Therapy.

Strategies to Achieve Immune Tolerance in Allogeneic Solid Organ Transplantation.

Cationic nanoparticles-based approaches for immune tolerance induction in vivo

Progress in Liver Transplant Tolerance and Tolerance-Inducing Cellular Therapies.

T regulatory cells as an immunotherapy for transplantation.

Advances in dendritic cell targeting nano-delivery systems for induction of immune tolerance

Regulatory T Cells and Their Derived Cell Pharmaceuticals As Emerging Therapeutics Against Autoimmune Diseases

Bioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases

Tolerogenic Nano-/Microparticle Vaccines for Immunotherapy.

[Research Progress of Cell Immunotherapy in Treatment of Hematological Malignancies-Review].

Adoptive Transfer of Regulatory Immune Cells in Organ Transplantation

The potential of mesenchymal stem cells to induce immune tolerance to allogeneic transplants

New strategies in immune tolerance induction

Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective